Technology Bundle ID: TAB-2251

Improved Standard for Immune System Recovery Assay

Request More Info
Licensing Contact:
Primary Inventors: 
Daniel Douek (NIAID)
Co-Inventors: 
Brenna Hill (NIAID), Richard Koup (NIAID)
Application: 
Research Materials
Development Status: 

Fully developed

Institute or Center: 
NIAID

Monitoring an immune system that has been depleted by infection (e.g., HIV), chemotherapy, or progenitor cell transplantation is vital to assessing individual’s recovery status. This technology provides a new plasmid standard to be used as part of the existing TREC assay. This new plasmid has a shorter insert than the commercially available one, which means it now matches the PCR product generated in the qPCR reaction in the TREC assay. Additionally, the new plasmid is easier to grow up than the existing standard.

Applications:
  • TREC assay for T cell concentration measurements
Advantages:
  • The insert of standard plasmid is shorter and directly matches the PCR product generated in the qPCR reaction
  • The standard plasmid is easy to grow up

Patents

EIR Application

Research Material (TREC DNA in carrier plasmid) — Patent protection is not being pursued for this technology. (IC Reference No. 2010-037)

Publications

Douek DC, et al.
PMID 10866444
Douek DC, et al.
PMID 9872319

Updated

Apr 29, 2011

Data Source: 
tts